Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.

Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market

Ginkgo Bioworks Holdings, Inc. (DNA, Financial) experienced a significant decline in its stock price, dropping 5.04% to $7.92 per share with a trading volume of 354,386 shares and a turnover rate of 0.64%. The price fluctuation reached 6.59%.

Ginkgo Bioworks (DNA) Shares Drop Amid Weak Earnings and Sell Ratings

BOSTON & OTTAWA, Ontario--(BUSINESS WIRE)-- #AAV--Virica and Ginkgo announce a strategic partnership to enhance the productivity of adeno-associated virus (AAV) gene therapy manufacturing platforms.

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.70, moving -0.77% from the previous trading session.

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade

BOSTON and CHESTERFIELD, Mo. , Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry.

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA):

Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

BOSTON , Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient.

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

The biotech rolled out two new healthtech innovations. One is a large language model (LLM) developed with its partner Alphabet.

Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API programmable interface now available for individual scientists and researchers to quickly test and advance work BOSTON , Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that will make it easier for pharmaceutical and biotech companies to develop new medicines, building on the partnership announced with Google Cloud last year.

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Ginkgo Bioworks hopes to revolutionize many industries with bioengineered products. Its business, however, remains deeply unprofitable.

Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?

BOSTON , Sept. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the Company's 30-day trading average closed above $1.00, Ginkgo had regained compliance with Section 802.01C of the NYSE Listed Company Manual.

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the public warrants (the “Warrants”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) — ticker symbol DNA.WS — each Warrant exercisable for one-fortieth (1/40) of one share of the Company's Class A common stock, par value $0.0001 per share (the “Class A common stock”), at an exercise price of $11.50 per Warrant, from.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Ginkgo Bioworks Holdings, Inc. (DNA.WS)

OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA):

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue.

2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock

Advance Auto Parts

Dollar General

Dumpster diving can be a lucrative pastime. One man's trash is another's treasure.

3 Stocks Hitting New 52-Week Lows. Should You Back Up the Truck?

Ginkgo Bioworks seeks to create a high-throughput biopharma services platform. So far, that platform isn't profitable, but it can still generate a lot of scientific data.

This 1 AI Stock Could Revolutionize Biotech and Pharma

BOSTON , Aug. 30, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET. Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

“Our revenue has grown substantially, and we are proud of the progress we've made in establishing strategic partnerships. The robust pipeline of projects we have in place positions us well for continued financial success.

From Promise to Peril: The Downfall of Ginkgo Bioworks

Ginkgo Bioworks is still not anywhere close to being operationally profitable. Management isn't planning on it becoming profitable anytime soon.

Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?

Ginkgo Bioworks has struggled with missed revenue targets, leading to a significant decline in share value. The recent Q2 report showed a 30% decrease in total revenues, with cost structure still a major issue for the company. Balance sheet weakening as cash reserves decrease, putting pressure on working capital and financial flexibility.

Ginkgo Bioworks: Here Comes The Test

Ginkgo Bioworks' market cap has plummeted from more than $25 billion at its peak to less than $600 million at recent prices. The company has announced heaps of layoffs this year in response to heavy losses.

Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?

Recursion Pharmaceuticals

AI holds tremendous promise for the biopharma industry. Using AI to identify candidates for new drugs is already happening.

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force  BOSTON , Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Second Quarter 2024 Financial Results

The Global Agriculture Biologicals Testing Market Size was Valued at USD 2.80 Billion in 2023 and the Worldwide Agriculture Biologicals Testing Market Size is Expected to Reach USD 5.61 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ALS Group, Anadiag Group, Bionema Group Limited, BioTecnologie BT, Eurofins APAL Pty Ltd, Eurofins Scientific SE, i2LResearch, Lallemand Inc., LAUS GmbH, R J Hill Laboratories Limited, SGS SA, Staphyt SA, SynTech Research Group, and Others The Global Agriculture Biologicals Testing Market Size was Valued at USD 2.80 Billion in 2023 and the Worldwide Agriculture Biologicals Testing Market Size is Expected to Reach USD 5.61 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ALS Group, Anadiag Group, Bionema Group Limited, BioTecnologie BT, Eurofins APAL Pty Ltd, Eurofins Scientific SE, i2LResearch, Lallemand Inc., LAUS GmbH, R J Hill Laboratories Limited, SGS SA, Staphyt SA, SynTech Research Group, and Others

News for Ginkgo Bioworks Holdings Stock (DNA)